---
title: "Sumitomo Pharma rejects Gotham City Research report on AMCHEPRY, Sumitomo Chemical says"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295590435.md"
description: "Sumitomo Pharma rejected a Gotham City Research report on AMCHEPRY, citing the publisher's short positions as a conflict of interest. The company defended the drug's regulatory reliability and ongoing Phase 4 studies for full approval. Additionally, Sumitomo Pharma warned of potential legal action regarding an Aug. 3 financial reporting report, alleging misleading information."
datetime: "2026-08-11T23:33:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295590435.md)
  - [en](https://longbridge.com/en/news/295590435.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295590435.md)
generator: "portal-rs"
---

# Sumitomo Pharma rejects Gotham City Research report on AMCHEPRY, Sumitomo Chemical says

-   Sumitomo Chemical flagged a statement from subsidiary Sumitomo Pharma disputing a Gotham City Research report published Aug. 7, 2026. \* Sumitomo Pharma rejected the report’s assertions, noting the publisher disclosed short positions that could profit from a share-price decline. \* Sumitomo Pharma defended AMCHEPRY, citing reliability of regulatory submissions, conditional time-limited approval, ongoing Phase 4 study toward full approval. \* The unit also referenced an Aug. 3, 2026 report on financial reporting, warning of possible legal action over misleading information. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Chemical Co. Ltd. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [4506.JP](https://longbridge.com/en/quote/4506.JP.md)
- [4005.JP](https://longbridge.com/en/quote/4005.JP.md)

## Related News & Research

- [Sumitomo Pharma (TSE:4506) Reports Strong First Quarter Earnings, Is The Discount Too Deep?](https://longbridge.com/en/news/295441766.md)
- [Poxel expects 2026 TWYMEEG Japan royalties to rise to 12% on Sumitomo sales forecast](https://longbridge.com/en/news/294406043.md)
- [Does Sumitomo Warehouse’s Q1 Beat And Steady Dividend Outlook Shift The Bull Case For TSE:9303?](https://longbridge.com/en/news/296646936.md)
- [Sumitomo Heavy Industries to exhibit cryocoolers at Applied Superconductivity Conference ASC 2026](https://longbridge.com/en/news/296718956.md)
- [2,957 Shares in Norfolk Southern Corporation $NSC Acquired by Sumitomo Life Insurance Co.](https://longbridge.com/en/news/296698418.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**